Lilly Forteo Follow-Up Rat Osteosarcoma Study To Finish By End Of 2002
Executive Summary
Lilly's follow-up Forteo (teriparatide) osteosarcoma study is expected to be completed by the end of 2002, FDA told the Endocrinologic and Metabolic Drugs Advisory Committee July 27.
You may also be interested in...
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Lilly Cialis Delay Clears Space For Bayer Nuviva: Extra FDA Caution Cited
The delay in the FDA review of Lilly/Icos' Cialis creates an opening for Bayer to establish Nuviva as the primary challenger to Pfizer's Viagra in the oral erectile dysfunction class